Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Non-Current Assets (2018 - 2025)

Historic Other Non-Current Assets for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $2.9 million.

  • 10x Genomics' Other Non-Current Assets fell 2945.02% to $2.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.9 million, marking a year-over-year decrease of 2945.02%. This contributed to the annual value of $2.9 million for FY2025, which is 2945.02% down from last year.
  • 10x Genomics' Other Non-Current Assets amounted to $2.9 million in Q4 2025, which was down 2945.02% from $1.9 million recorded in Q3 2025.
  • 10x Genomics' 5-year Other Non-Current Assets high stood at $31.5 million for Q1 2021, and its period low was $1.9 million during Q3 2025.
  • Over the past 5 years, 10x Genomics' median Other Non-Current Assets value was $6.1 million (recorded in 2022), while the average stood at $9.8 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first surged by 18838.62% in 2023, then plummeted by 7788.32% in 2024.
  • 10x Genomics' Other Non-Current Assets (Quarter) stood at $8.6 million in 2021, then decreased by 11.81% to $7.6 million in 2022, then crashed by 59.75% to $3.1 million in 2023, then surged by 34.85% to $4.1 million in 2024, then dropped by 29.45% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q4 2025, $1.9 million for Q3 2025, and $2.7 million during Q2 2025.